E7090 (succinate)

• Description:

  E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively[1].

• UNSPSC:

  12352005

• Target:

  FGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/e7090-succinate.html

• Purity:

  99.17

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (O) CCC (O) =O.O=C (N1C=CC2=C1C=C (OCCOC) C (OC3=CC (NC (C4=CC=C (C5CCN (CCO) CC5) C=C4) =O) =NC=C3) =C2) NC.[3/2]

• Molecular Formula:

  C32H37N5O6.3/2C4H6O4

• Molecular Weight:

  764.82

• References & Citations:

  [1]Saori Watanabe Miyano, et al. E7090: A potent and selective FGFR inhibitor with activity in multiple FGFR-driven cancer models with distinct mechanisms of activation. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.|[2]Saori Watanabe Miyano, et al. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. Mol Cancer Ther. 2016 Nov;15 (11) :2630-2639.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  1879965-80-6